Compare · BLFS vs LIVN
BLFS vs LIVN
Side-by-side comparison of BioLife Solutions Inc. (BLFS) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLFS and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.43B, about 3.1x BLFS ($1.42B).
- Over the past year, BLFS is up 40.2% and LIVN is up 90.5% - LIVN leads by 50.3 points.
- BLFS has hit the wire 3 times in the past 4 weeks while LIVN has been quiet.
- LIVN has more recent analyst coverage (20 ratings vs 8 for BLFS).
- Company
- BioLife Solutions Inc.
- LivaNova PLC
- Price
- $29.11-3.83%
- $80.70-1.27%
- Market cap
- $1.42B
- $4.43B
- 1M return
- +10.60%
- +1.54%
- 1Y return
- +40.15%
- +90.48%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 0
- Recent ratings
- 8
- 20
BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest BLFS
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 844 shares, decreasing direct ownership by 0.39% to 213,249 units (SEC Form 4) (withholding obligation)
- EVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 516 shares, decreasing direct ownership by 0.13% to 388,460 units (SEC Form 4) (for tax liability)
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 293 shares, decreasing direct ownership by 0.18% to 162,649 units (SEC Form 4) to cover taxes
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 470 shares, decreasing direct ownership by 0.29% to 162,942 units (SEC Form 4) (tax liability)
- Chief Technology Officer Werner Sean covered exercise/tax liability with 420 shares, decreasing direct ownership by 0.87% to 47,831 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 937 shares, decreasing direct ownership by 0.44% to 214,093 units (SEC Form 4) to cover taxes
- EVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 564 shares, decreasing direct ownership by 0.14% to 388,976 units (SEC Form 4) to cover taxes
- President and CEO De Greef Roderick covered exercise/tax liability with 2,775 shares, decreasing direct ownership by 0.38% to 730,971 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 1,026 shares, decreasing direct ownership by 0.47% to 215,030 units (SEC Form 4) (withholding obligation)
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 356 shares, decreasing direct ownership by 0.22% to 163,412 units (SEC Form 4) (tax withholding)
Latest LIVN
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
- Director Bianchi Francesco covered exercise/tax liability with 486 units of Ordinary Shares, sold $96,228 worth of Ordinary Shares (1,200 units at $80.19) and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 33% to 9,584 units (SEC Form 4)
- Director Podlogar Susan M converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 170% to 5,642 units (SEC Form 4)
- Director Schermerhorn Todd C converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 39% to 12,619 units (SEC Form 4)
- SEC Form 4 filed by Director Nygaard-Andersen Jette
- Director Enxing Seng Stacy converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 30% to 15,307 units (SEC Form 4)
- Director Kozy William A converted options into 5,681 units of Ordinary Shares and covered exercise/tax liability with 682 units of Ordinary Shares, increasing direct ownership by 15% to 37,566 units (SEC Form 4)
- Director Barry James Christopher covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 82% to 7,918 units (SEC Form 4)